If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine) injection
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is Basaglar® (insulin glargine) therapy initiated and titrated?
The recommended initial dose of Basaglar is approximately one-third of the total daily insulin requirement for type 1 diabetes and up to 10 units once daily for type 2 diabetes. For type 2 diabetes, a titration schedule of 1 unit per day was used.
Initiation of Basaglar Therapy
The recommended initial dose of Basaglar® (insulin glargine) 100 units/mL differs between patients with type 1 or type 2 diabetes (Initiation of Basaglar Therapy in Patients With Type 1 or Type 2 Diabetes).1
If treating patients with... |
Then the recommended initial dose of Basaglar is... |
type 1 diabetes |
approximately 1/3 of the total daily insulin requirement. |
type 2 diabetes |
0.2 units/kg or up to 10 units once daily. |
Abbreviation: Basaglar = Basaglar® (insulin glargine) 100 units/mL.
In patients with type 1 diabetes, short- or rapid-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirement.1
In patients with type 2 diabetes, dosage adjustments of concomitant antihyperglycemic medications may be needed.1
Titration of Basaglar Therapy During a Phase 3 Clinical Study: ELEMENT 2
ELEMENT 2 was a randomized, double-blind, phase 3 study that compared the efficacy and safety of Basaglar vs Lantus® (insulin glargine) 100 units/mL in patients with type 2 diabetes.2
The initial dose of Basaglar and Lantus for insulin-naïve patients was 10 units once daily.2
Patients previously prescribed Lantus initiated Basaglar or Lantus at the prestudy Lantus dose.2
As described by Gerstein et al, patients followed a patient-driven titration schedule to increase their initial insulin dose by 1 unit daily until a fasting plasma glucose concentration of ≤100 mg/dL was achieved.2,3
In Korea and Taiwan, due to the availability of syringes only marked in 2-unit increments, patients followed a patient-driven titration schedule to increase their initial dose by 2 units every other day until a fasting blood glucose concentration of ≤100 mg/dL was achieved.4
Higher insulin dose increases were permitted if deemed necessary by the investigator, and insulin dose decreases were permitted if patients experienced hypoglycemia.4
Approximately 50% of patients in each treatment group injected their basal insulin in the daytime and approximately 50% of patients injected their dose in the evening or at bedtime.4
Titration of Insulin Glargine Therapy
In the Canadian INSIGHT, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment, study with 405 insulin-naïve patients, introduction of insulin glargine and self-titration of the insulin glargine dose by a simple protocol of 1 unit per day was 1.7 times more likely to safely achieve near-physiological control, defined as 2 consecutive glycated hemoglobin (HbA1c) levels <6.5%, than conventional therapy with oral antihyperglycemic medications.3
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
2Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734-741. https://doi.org/10.1111/dom.12482
3Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med. 2006;23(7):736-742. http://dx.doi.org/10.1111/j.1464-5491.2006.01881.x
4Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: March 14, 2024